Deep-Dive

Deep-Dive

Every two weeks, we delve into detailed analyses of the latest policy initiatives, funding mechanisms, and healthcare delivery channels impacting access to innovative medicines in China.
Aug
30
Improving Access to Innovative Drugs: Can China’s Dual-Channel Policy Deliver?

Improving Access to Innovative Drugs: Can China’s Dual-Channel Policy Deliver?

To tackle the hospital formulary access issues faced by some NRDL-negotiated drugs, the National Healthcare Security Administration (NHSA) introduced the
5 min read
Aug
16
Shanghai Enhances Payment Mechanisms to Drive Pharma and Medical Innovation

Shanghai Enhances Payment Mechanisms to Drive Pharma and Medical Innovation

Shortly after the National Healthcare Security Administration (NHSA) introduced its more industry-friendly renewal rules for older NRDL-negotiated drugs, the Shanghai
6 min read
Aug
02
China Implements More Moderate and Predictable Price Reduction for Older NRDL-Negotiated Drugs

China Implements More Moderate and Predictable Price Reduction for Older NRDL-Negotiated Drugs

In late June, the National Healthcare Security Administration (NHSA) commenced the 2023 National Reimbursement Drug List (NRDL) Dynamic Update, aiming
4 min read
Jul
05
Behind the Scenes: Exploring the Roadblocks to Formulary Listing for NRDL-Negotiated Drugs in China Public Hospitals

Behind the Scenes: Exploring the Roadblocks to Formulary Listing for NRDL-Negotiated Drugs in China Public Hospitals

China's National Reimbursement Drug List (NRDL) is increasingly incorporating innovative drugs. Once included in the NRDL, these drugs
6 min read
Jun
21
Navigating China's Access Landscape for Orphan Therapies: Insights into Funding Pathways

Navigating China's Access Landscape for Orphan Therapies: Insights into Funding Pathways

Welcome back to the final installment of our three-part series exploring China's access landscape of rare disease therapies.
12 min read
Jun
07
Understanding China’s Access Environment for Orphan Therapies: Advancing Policies and Diagnosis & Treatment Capacities

Understanding China’s Access Environment for Orphan Therapies: Advancing Policies and Diagnosis & Treatment Capacities

In our previous installment, we delved into the distinctive characteristics and commercial challenges surrounding rare diseases, highlighting a comprehensive solution
10 min read
May
24
Understanding China’s Access Environment for Orphan Therapies: 3 Key Considerations

Understanding China’s Access Environment for Orphan Therapies: 3 Key Considerations

Biopharmaceutical companies face distinctive challenges when it comes to developing and commercializing treatments for rare diseases, as these conditions affect
7 min read
May
10
How China’s Provider Payment Reform Will Impact Key Healthcare Stakeholders

How China’s Provider Payment Reform Will Impact Key Healthcare Stakeholders

Our last article discussed the context behind the DRG/DIP payment reform and how China has adopted this dual-track payment
9 min read
May
03
Understanding China's Dual-Track DRG DIP Provider Payment Reform

Understanding China's Dual-Track DRG DIP Provider Payment Reform

China has undergone a significant transformation in its healthcare system in recent years. One central area of reform has been
6 min read
Apr
26
Access Pathway for Innovative Medicines in China: Pure Commercial Health Insurance

Access Pathway for Innovative Medicines in China: Pure Commercial Health Insurance

In the last installment, we introduced City Commercial Health Insurance (City CHI), a type of all-inclusive commercial health insurance positioned
5 min read